VCYT
Veracyte, Inc.
$44.08
-1.17
(-2.59%)
Mkt Cap
3.61B
Volume
693,584
52W Range
29.375-60.91
Sector
Healthcare
Beta
1.94
EPS (TTM)
1.44 USD
P/E Ratio
31.42
Revenue (TTM)
561.90M USD
Rev Growth (5Y)
+34.5%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$50.83
Fair Value
weak signal
11.0% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 517.14M | 445.76M | 361.05M | 296.54M | 219.51M | 117.48M | 120.37M | 92.01M | 71.95M | 65.08M | 49.50M | 38.19M |
| Net Income | 66.35M | 24.14M | (74.40M) | (36.56M) | (75.56M) | (34.91M) | (12.60M) | (23.00M) | (31.00M) | (31.36M) | (33.70M) | (29.37M) |
| EPS | 0.84 | 0.32 | -1.02 | -0.51 | -1.11 | -0.66 | -0.27 | -0.62 | -0.91 | -1.09 | -1.30 | -1.36 |
| Free Cash Flow | 126.63M | 63.81M | 34.26M | (1.01M) | (37.00M) | (12.55M) | (5.99M) | (15.39M) | (25.67M) | (32.19M) | (33.13M) | (29.66M) |
| FCF / Share | 1.61 | 0.83 | 0.47 | -0.01 | -0.54 | -0.24 | -0.13 | -0.42 | -0.76 | -1.12 | -1.28 | -1.37 |
| Operating CF | 136.31M | 75.10M | 44.22M | 7.54M | (31.62M) | (9.71M) | (3.23M) | (13.52M) | (23.91M) | (27.98M) | (26.96M) | (27.63M) |
| Total Assets | 1.41B | 1.30B | 1.11B | 1.16B | 1.19B | 457.16M | 275.21M | 120.64M | 78.67M | 101.03M | 75.28M | 64.84M |
| Total Debt | 39.65M | 50.74M | 12.63M | 14.72M | 18.85M | 12.32M | 13.61M | 25.28M | 25.25M | 25.52M | 5.03M | 4.92M |
| Cash & Equiv | 362.58M | 239.09M | 216.45M | 154.25M | 173.20M | 349.36M | 159.32M | 78.00M | 33.89M | 59.22M | 39.08M | 35.01M |
| Book Value | 1.31B | 1.18B | 1.04B | 1.08B | 1.10B | 421.23M | 239.46M | 79.75M | 37.23M | 59.58M | 51.25M | 41.37M |
| Return on Equity | 0.05 | 0.02 | -0.07 | -0.03 | -0.07 | -0.08 | -0.05 | -0.29 | -0.83 | -0.53 | -0.66 | -0.71 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 150.32M | 139.07M | 140.64M | 131.87M | 130.16M | 114.47M | 118.63M | 115.86M | 114.43M | 96.84M | 98.20M | 90.11M |
| Net Income | 25.49M | 28.71M | 41.15M | 19.14M | (980,000) | 7.05M | 5.11M | 15.15M | 5.73M | (1.86M) | (28.29M) | (29.62M) |
| EPS | 0.32 | 0.36 | 0.52 | 0.24 | -0.01 | 0.09 | 0.07 | 0.20 | 0.07 | -0.02 | -0.39 | -0.41 |
| Free Cash Flow | 42.97M | 32.25M | 48.27M | 41.97M | 32.32M | 3.54M | 20.38M | 27.72M | 26.80M | (11.10M) | 13.05M | 11.37M |
| FCF / Share | 0.54 | 0.41 | 0.61 | 0.53 | 0.41 | 0.05 | 0.26 | 0.36 | 0.35 | -0.15 | 0.18 | 0.16 |
| Operating CF | 45.83M | 35.22M | 52.58M | 44.76M | 33.60M | 5.36M | 24.52M | 29.96M | 29.57M | (8.97M) | 15.55M | 14.17M |
| Total Assets | 1.49B | 1.44B | 1.41B | 1.37B | 1.34B | 1.32B | 1.30B | 1.28B | 1.23B | 1.20B | 1.11B | 1.12B |
| Total Debt | 40.11M | 39.33M | 39.65M | 40.45M | 50.65M | 50.50M | 50.74M | 19.69M | 20.74M | 14.04M | 12.63M | 13.73M |
| Cash & Equiv | 299.52M | 263.14M | 362.58M | 315.57M | 219.50M | 186.12M | 239.09M | 274.08M | 235.91M | 209.19M | 216.45M | 202.46M |
| Book Value | 1.39B | 1.34B | 1.31B | 1.26B | 1.22B | 1.19B | 1.18B | 1.18B | 1.13B | 1.12B | 1.04B | 1.05B |
| Return on Equity | 0.02 | 0.02 | 0.03 | 0.02 | -0.00 | 0.01 | 0.00 | 0.01 | 0.01 | -0.00 | -0.03 | -0.03 |
VCYT News
Bamco Inc. NY Invests $38.22 Million in Veracyte, Inc. $VCYT
Is it Worth Adding Veracyte Stock to Your Portfolio Now?
VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?
Down 30.2% in 4 Weeks, Here's Why Veracyte (VCYT) Looks Ripe for a Turnaround
Bank of America Corp DE Grows Stock Position in Veracyte, Inc. $VCYT
Veracyte: Diagnostics With Favorable Economics
Veracyte: Core Growth Funds Prosigna And TrueMRD
Veracyte, Inc. (VCYT) Q2 2026 Earnings Call Transcript
Veracyte (VCYT) Q2 Earnings and Revenues Surpass Estimates
Veracyte Announces Second Quarter 2026 Financial Results